July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Programmed Death Ligand 1 Protects Against Experimental Laser-Induced Choroidal Neovascularization in Mice
Author Affiliations & Notes
  • Xiaohong Wang
    Tianjin Medical University, Tianjin, China
  • Hua Yan
    Tianjin Medical University, Tianjin, China
  • Yunli Huang
    Tianjin Medical University, Tianjin, China
  • Footnotes
    Commercial Relationships   Xiaohong Wang, None; Hua Yan, None; Yunli Huang, None
  • Footnotes
    Support  National Natural Science Foundation of China (Grant Numbers 81830026, 81670865)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 773. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiaohong Wang, Hua Yan, Yunli Huang; Programmed Death Ligand 1 Protects Against Experimental Laser-Induced Choroidal Neovascularization in Mice. Invest. Ophthalmol. Vis. Sci. 2019;60(9):773.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
We investigate the therapeutic effect of Programmed Death Ligand 1(PD-L1)by downregulating autoreactive T cells on experimental laser-induced choroidal neovascularization (CNV) in mice.

Methods : After CNV was induced by laser photocoagulation in 200 female C57BL/6 mice, PD-L1, anti–PD-L1 antibody or PBS was injected by tail vein on 14th day after laser injury. Fluorescein angiography was performed on the 3rd day, the 7th day, the 14th day and the 21st day to grade CNV leakage after injection. The CNV volume was measured by confocal microscopy in eyes enucleated 3 days, 7 days, 14 days and 21 days after injection. Immune cells in peripheral blood were measured by flow cytometry.

Results : Tail intravenous administration of PD-L1 significantly suppressed CNV leakage and CNV volume (P < 0.01). PD-L1 treatment inhibited lymphocyte proliferation and altered T cell differentiation by inducing decrease in IFN-γ+CD4+ Th1 cells and IL-17+CD4+ Th17 cells and increase in Foxp3+CD4+ regulatory T cells. The administration of anti–PD-L1 antibody produced the opposite effects to those of PD-L1 in CNV mice.

Conclusions :
Tail intravenous administration of PD-L1 suppressed laser-induced CNV by its anti-inflammatory and alteration of T cell differentiation. The current results suggested that PD-L1 may be a potential therapeutic adjuvant for treating CNV.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×